Alflutinib Enrolling by Invitation Phase 2 Trials for Non-Small Cell Lung Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
Enrolling by InvitationTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT05813522Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC